2014 Annual Meeting of the American Association for the Study of Liver Diseases*

November 7-11, 2014; Boston, Massachusetts
CCO’s Official Conference Coverage of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases includes Capsule Summaries, reviews by expert faculty on key studies highlighted at the conference, and downloadable slides.

Highlights from the Meeting


SVR12 rates ≥ 90% were attained regardless of RBV use or treatment duration.

Released: November 13, 2014

97% of patients in this historically challenging patient population achieved SVR12, with no episodes of acute or chronic liver graft rejection.

Released: November 14, 2014

Among the 50 patients with genotype 1 HCV infection in this study, 100% achieved SVR12 after 12 weeks of retreatment; single relapse was misclassified patient later found to have genotype 3a HCV infection.

Released: November 14, 2014

High SVR12 rates and improved liver function with low rates of treatment-emergent adverse events.

Released: November 14, 2014

To date, regimens allowing removal of peginterferon most commonly selected: sofosbuvir plus ribavirin in patients with genotype 2/3 infection and sofosbuvir plus simeprevir with or without ribavirin in genotype 1 HCV infection.

Released: November 11, 2014

Low levels of discontinuation due to adverse events; no virologic failure with 100-mg dose of GS-5816. Inclusion of ribavirin associated with more frequent adverse events with no efficacy benefit.

Released: November 12, 2014

In this phase II trial, sofosbuvir plus GS-5816 with or without ribavirin was generally safe and well tolerated with only 1 patient discontinuing treatment because of adverse events.

Released: November 13, 2014

In logistic regression analysis, IL28B TT genotype, previous null response to peginterferon/ribavirin, and genotype 1a HCV only factors significantly associated with not achieving SVR12.

Released: November 14, 2014

Similar SVR12 rates with 24-week ribavirin-free regimen vs 12-week ribavirin-containing regimen in treatment-experienced cirrhotics.

Released: November 10, 2014

The addition of ribavirin resulted in higher SVR rates, and extension of therapy to 24 weeks beneficial for cirrhotic patients with a previous null response to peginterferon/ribavirin.

Released: November 14, 2014

Reduced relapse rates with RBV-containing vs RBV-free regimens in both treatment-naive and treatment-experienced cirrhotic patients with genotype 1a receiving daclatasvir/asunaprevir/beclabuvir.

Released: November 17, 2014

SVR12 rates substantially lower for both treatment-naive and treatment-experienced cirrhotics vs noncirrhotics.

Released: November 13, 2014

SVR4/8 rates higher in patients with genotype 1b HCV infection, IL28B CC genotype, or lower baseline HCV RNA level.

Released: November 14, 2014

SVR12 rate of approximately 90% for both treatment-naive and treatment-experienced patients.

Released: November 14, 2014
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
Janssen Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?